ACT Brief: Thermo Fisher Acquires Clario, Wearables and AI Integration, and Somatic Genomics for IBD

This is the Applied Clinical Trials Brief — your fast track to the latest insights shaping clinical operations and drug development.

• Thermo Fisher Scientific completed its $8.875 billion acquisition of Clario, which integrates clinical trial endpoint data from devices, sites, and patients across drug development phases. The deal positions Thermo Fisher to deepen its presence at the intersection of clinical operations and data intelligence, with Clario technology supporting approximately 70% of FDA and EMA novel drug approvals over the past decade.
• In a new Q&A, Mohammed Saeed, MD, PhD, chief medical officer at Solera Health, discussed wearable integration across five key areas: capturing real-world patient health outside the clinic, enabling early intervention through continuous monitoring, addressing data overload and alert fatigue challenges, building FDA clearance and reimbursement models, and leveraging AI to identify subtle clinical patterns imperceptible to clinicians.
• Merck entered a multi-year collaboration with Quotient Therapeutics to identify novel IBD drug targets using somatic genomics analysis of naturally occurring genetic mutations in diseased tissue. Quotient's platform can identify disease-driving or disease-protective mutations from small patient cohorts of 10 to 30 individuals and uses AI-enabled analytics to accelerate target identification and validation, potentially uncovering new therapeutic pathways.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.